Phase 1 Interstitial Lung Disease Trial, Recruiting NCT06992661 Sponsor: Ruijin Hospital Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 1 Interstitial Lung Disease Trial, Recruiting

NCT06992661
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 40 years of age or older, of any gender
  • You have been diagnosed with, or are suspected to have, a lung scarring condition called ILD (specifically IPF or CTD-ILD), confirmed by a type of chest scan (CT scan)
  • Your lung function tests show your lungs are working at least 40% of expected capacity for two key measurements, and your breathing airways are not significantly narrowed (confirm with trial site if unsure about your results)
  • You are able to undergo a procedure called a bronchoscopy, where a thin tube is passed into your airways to examine your lungs
  • You are willing to use effective birth control throughout the study period
  • You are able to use an inhaler device correctly

Who may not be able to join:

  • You are currently pregnant or breastfeeding
  • You have a known allergy to any ingredient in the study medication
  • You currently have an active chest or breathing infection, or a serious heart or lung condition that has recently become worse
  • Your liver function blood tests show results that are above the normal range
  • You have smoked within the last 6 months, or you have issues with excessive alcohol use
  • You have taken part in another clinical trial within the last 3 months
  • You have donated 400mL or more of blood within the last 3 months
  • You have certain levels of hepatitis B, hepatitis C, or you are HIV positive (confirm specific threshold details with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
15 May 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

AUC0-24 hours of blood samples in ILD patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov